非布司他治疗时要注意什么？

(Also known as: Febuxostat) is a newly developed XOR retardant in the world. It can selectively act on this antibiotic through a high degree of efficiency, reduce the production of blood uric acid in the body, lower cholesterol levels, and thus effectively treat ventilation diseases.

Febuxostat has a significant inhibitory effect on both air-oxidized and reduced XOR. What should we pay attention to when treating Febuxostat?

Precautions for Febuxostat:

1. Gout flare-ups: An increase in flare-ups of gout is often observed during the initiation of antiuricemic drugs, including febuxostat. If a gout attack occurs during treatment, febuxostat does not need to be discontinued. Preventive treatment (i.e., initiating treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or colchicine) may be beneficial until 6 months of age.

2. Cardiovascular events: In clinical trials, a higher incidence of cardiovascular embolic events was observed in patients treated with febuxostat than with allopurinol. Monitor for signs and symptoms of MI and stroke.

3. Elevated liver enzymes: Elevated transaminases have been observed in patients treated with febuxostat. Monitor liver function tests regularly.

4. In the early stages of treatment, the rapid decrease in blood uric acid value may cause more urate deposited in tissues to be mobilized, leading to an increase in the frequency of gout attacks.

5. To prevent gout attacks in the early stages of treatment, it is recommended to start with a small dose and gradually increase the dose, and use colchicine and non-steroidal anti-inflammatory drugs (such as ibuprofen, etc.) under the guidance of a doctor.

6. Patients with acute attacks of gout need to control gout symptoms before use. If a gout attack occurs during treatment with febuxostat (also known as febuxostat), there is no need to discontinue treatment with febuxostat. Gout should be treated accordingly based on the specific circumstances of the attack.

Recommended related hot articles: /newsDetail/74682.html